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Figure 3. Standardized mean differences of active treatments for pain at
12 weeks comparing results from deferential placebo effect network and
single placebo effect network
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56 S25Results: We identiﬁed 140 studies including 37,908 participants with
an age range of 45 - 75 years. The proportion of women ranged
from 28% - 100%. For pain, IA placebo (SMD, 95% Credible Interval)
[0.28 (0.08, 0.48)] and topical placebo [0.20 (0.02, 0.38)] had sig-
niﬁcantly greater effects than oral placebo. The relative efﬁcacies and
the hierarchy of the active treatments were substantially changed by
ignoring the differential response to the placebo types (Figures 2 &
3). For example, in the differential placebo network model, IA and
topical therapies rank higher than oral, while in the non-differential
placebo network model, oral NSAIDs ranked higher.
Conclusions: Our results show that some types of placebo inter-
ventions are associated with greater responses. This supports the
notion that some placebo treatments can exert clinically relevant
effects. In other words, the method of treatment delivery might
have an important inﬂuence on outcome. These important differ-
ences also need to be accounted for in the design of future OA
studies.
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RANDOMIZED, DOUBLE-BLIND, MULTICENTER, NON INFERIORITY
CLINICAL TRIAL WITH COMBINED GLUCOSAMINE AND
CHONDROITIN SULFATE VS CELECOXIB FOR PAINFUL KNEE
OSTEOARTHRITIS
M.C. Hochberg y, J. Martel-Pelletier z, J. Monfort x, I. M€oller k,
P. du Souich{, J.-P. Pelletier z, MOVES Steering Committee. yDiv. of
Rheumatology & Clinical Immunology, Univ. of Maryland Sch. of Med.,
Baltimore, MD, USA; zOsteoarthritis Res. Unit Univ. of Montreal Hosp.
Res. Ctr. (CRCHUM), Montreal, QC, Canada; xRheumatology Dept., Hosp.
del Mar, Barcelona, Spain; k Inst. POAL de Reumatologia, Barcelona,
Spain; { Pharmacology Dept., Faculty of Med., Univ. of Montreal,
Montreal, QC, Canada
Purpose: The ﬁxed dose combination of glucosamine hydrochloride
and chondroitin sulfate (2 capsules GHclþCS; 250 mg and 200 mg,
respectively, three times daily) was found to be efﬁcacious compared to
placebo in subjects with knee osteoarthritis (OA) with severe pain in the
NIH-funded Glucosamine Arthritis Intervention Trial (GAIT) (N Engl J
Med 2006 Feb 23;354(8):795-808). The proportion of OA patients who
achieved the primary endpoint of a 20% improvement in pain was
similar between those randomized to GHclþCS and celecoxib 200 mg
daily in this 6-month symptom study. Subsequently, a phase IV
randomized controlled non-inferiority trial was designed to compare
the efﬁcacy of GHclþCS and celecoxib in patients with knee OA to
extend the ﬁndings from GAIT.
Methods: The Multicentric Osteoarthritis interVEntion Study with
Sysadoa (MOVES) was designed as a non-inferiority trial to compare the
efﬁcacy and safety of a ﬁxed dose combination of GHclþCS (Droglican,
Bioiberica SA, Barcelona, Spain) and celecoxib in patients with symp-
tomatic knee OA with severe pain. Patients were randomized in a
double-blind, double-dummy fashion to receive either 2 capsules of
Droglican (GHcl 250 mg and CS 200 mg) three times daily, or Celecoxib
200 mg capsule plus 5 placebo Droglican capsules per day. Patients
were eligible if they were aged 40 and above, fulﬁlled American College
of Rheumatology criteria for knee OA, had Kellgren-Lawrence (KL) grade2 or 3 radiographic severity and had a WOMAC pain scale of >301 units
(0-500 scale). Patients with high gastrointestinal or cardiovascular risk
were excluded. The primary outcome was the mean decrease in
WOMAC Pain subscale after 6 months of treatment; the non-inferiority
marginwas set at 40 (corresponding to 8 mm on a 0-100 mm scale) and
the sample size was calculated at 240 per group with 90% power. Mixed
model repeated measures was used to analyse the primary outcome;
time, treatment and time x treatment were included as ﬁxed effects.
Results: A total of 763 patients were screened and 606 randomized to
receive either Droglican (N¼304) or celecoxib (N¼302). Of these, 522
(86.1%) completed the 6-month trial and were included in the per-
protocol non-inferiority analysis; there was no difference in proportion
completing between groups. Mean (SD) age was 62.7 (8.9) years, 438
(83.9%) were women; KL grade 2 changes were present in 327 (62.6%).
The mean (SD) WOMAC pain score at randomization was 372.0 (41.8)
and 370.6 (41.4) in the Droglican and celecoxib groups, respectively.
The mean (SD) WOMAC pain score at 180 days was 185.8 (7.4) and
184.7 (7.6) in the Droglican and celecoxib groups, respectively, corre-
sponding to a mean (SEM) difference of 1.11 (10.63) units (95% con-
ﬁdence interval -21.99, 19.76) (P ¼ 0.917) that respects the non-
inferiority margin. These results were robust in sensitivity analyses
using the intention-to-treat population and when baseline observation
carried forward was used for imputation in both the per-protocol and
intent-to-treat populations. In addition, there was no signiﬁcant dif-
ference between the Droglican and celecoxib groups in the absolute
improvement in the WOMAC stiffness and function scales and the ﬁve
individual items of the WOMAC pain scale at 6 months. There was no
signiﬁcant difference in the proportion of patients with treatment-
emergent adverse events between the groups (50.7% overall); no
deaths occurred in this 6-month study.
Conclusions: These results demonstrated comparable efﬁcacy of a ﬁxed
dose combination of glucosamine hydrochloride and chondroitin sul-
phate (Droglican) to celecoxib for relief of severe knee pain in patients
with knee OA and a similar safety proﬁle. Further ongoing analyses will
examine key secondary endpoints including responder indices in this
population.
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STUDY OF THE EFFECT OF CHONDROITIN SULFATE ON PAIN IN KNEE
OSTEOARTHRITIS PATIENTS ASSESSED BY FUNCTIONAL MRI: A
RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL
TRIAL
J. Monfort y, J. Pujol z, O. Contreras-Rodríguez z, J. Llorente-Onaindia y,
M. Lopez-Sola y,x, L. Blanco-Hinojo k,z, J. Deus y,{, H. Ortiz z,
F. Monta~nes y, M. Campillo y, L. Sanchez#, M. Herrero#, J. Verges #,
P. Benito y. yRheumatology Dept., Hosp. del Mar, Barcelona, Spain; zMRI
Res. Unit, CRC Mar, Hosp. del Mar, Barcelona, Spain; xDept. of
Psychology and NeuroSci.. Univ. of Colorado, Boulder, CO, USA; kHuman
Pharmacology and NeuroSci.s, Inst. of Neuropsychiatry and Addiction,
Hosp. del Mar Res. Inst., Barcelona, Spain; {Dept. of Clinical and
Hlth.Psychology, Autonomous Univ. of Barcelona, Barcelona, Spain;
# PharmaSci. Div., BIOIBERICA S.A., Barcelona, Spain
Purpose: The aim of the present fMRI study was to objectively identify
the effects of Chondroitin Sulfate (CS) treatment on the brain response
to pressure painful stimulation in patients with radiological and clinical
knee osteoarthritis.
Material and methods: The current study was developed in the
Rheumatology Department and the MRI Research Unit of the Hos-
pital del Mar in Barcelona, from December 2010 to January 2013. This
is a phase IV, randomized, double-blind clinical trial in which
patients received CS (Condrosan, Bioiberica S.A.) 800 mg/day or
placebo for a 4-month treatment course. 64 patients were random-
ized (32 to placebo and 32 to CS), and ﬁnally 51 patients were
evaluable by ITT (27 in the placebo group and 24 in the CS group).
Patients were assessed at baseline and post-treatment. Two tests
were conducted in each session by applying painful pressure on the
patella surface and on the knee medial interline, using a MRI-com-
patible algometer, during the acquisition of two 6-min fMRI
sequences. Stimulus intensity to be applied in both fMRI sessions was
individually adjusted prior to baseline fMRI. Each subject was asked
to rate the subjective pain perceived during the whole fMRI sequence
immediately after fMRI acquisition using NRS. All fMRI data were
processed using the Statistical Parametric Mapping (SPM8) package,
Wellcome Department of Imaging Neuroscience, running in Matlab
Abstracts / Osteoarthritis and Cartilage 22 (2014) S7–S56S267.1. One-sample t-statistic maps were calculated to describe task-
related activations, and ANOVA (SPM Full Factorial repeated meas-
urements within groups and independent between groups) was used
to identify group by session treatment interaction effects and to
compare groups and sessions. The main outcome measurement was
attenuation of the response evoked by knee painful stimulation in
the pain-processing brain system.
Results: Patients receiving CS showed a tendency to report reduced
subjective pain after treatment during patella pressure test (p¼0.077),
but no signiﬁcant group by session interaction was demonstrated. fMRI
of patella pain, showed a larger activation reduction in the CS group
than in placebo in a posterior mesencephalon region including the
periaqueductal gray (PAG). The entire PAG cluster (238 voxels) with
signiﬁcant interaction showed a pre>post-treatment difference at
p<0.05 (peak difference at x¼-4, y¼-40, z¼-16; t¼2.4, p¼0.01). In this
paired analysis, the CS group showed signiﬁcant activation reduction
in the primary somatosensory cortex (including the cortical repre-
sentation of the leg) and extending to the primary motor cortex and
posterior supplementary motor area. Group by session interaction
consistently revealed a tendency for this cortical change to be larger in
the CS than in placebo (peak interaction x¼2, y¼-6, z¼72; t¼2.96,
p¼0.002 and 43 voxels-subthreshold- with p<0.01) (Figure 1). No
effects of CS were detected using the knee interline pressure test.
Conclusions: The study succeeded in the primary objective as a sig-
niﬁcant effect was demonstrated showing attenuation of brain response
to painful pressure in key regions of the pain-processing network using
the patella test.
Despite knee medial interline is one of the most tenders points in
patients with knee osteoarthritis, pressure on this site may generate
pain from damage or sensitization in a variety of structures. The
pain generated by pressing down the patella surface, in contrast, is
probably less complex, and may be more selectively related to
sensitization processes in the bone and the junction between the
bone and cartilage as a result of erosion in the patella and femoral
cartilages. The observed positive treatment effect of CS is consistent
with the known CS action on cartilage protection due to chon-
drocyte regeneration. fMRI was able to objectify CS effects on brain
response to knee pressure painful stimulation, yielding further
support to the utility of fMRI to objectify treatment effects on OA
pain.
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A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-
CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND
SAFETY OF INTRA-ARTICULAR ONABOTULINUMTOXINA AS
TREATMENT FOR OSTEOARTHRITIS KNEE PAIN: RESULTS FROM
THE EXPERIMENTAL PAIN MODELS
L. Arendt-Nielsen y, G.-L. Jiang z, R. DeGryse z, C.C. Turkel z. yAalborg
Univ., Sch. of Med., Ctr. for Sensory-Motor Interaction, Aalborg E,
Denmark; zAllergan, Inc., Irvine, CA, USA
Purpose: Peripheral and central sensitization can worsen knee
osteoarthritis (OA) pain. Focally administered onabotulinumtoxinA
(onabotA) has caused analgesia via disruption of peripheral release of
neurogenic inﬂammatory mediators (eg, glutamate, gene-related
peptide, substance P), which in turn reduces peripheral nociceptive
drive and peripheral sensitization, resulting in modiﬁed central pain
mediation. Inhibition of peripheral nociception in knee OA by intra-
articular (IA) injection of onabotA may be a new treatment modality.
This study aimed to evaluate the efﬁcacy of a single onabotA IA
injection in knee OA pain using traditional pain assessments (eg, daily
pain diary) and mechanistic, quantitative, experimental pain assess-
ment models to proﬁle peripheral and central actions. Safety data were
also collected.
Methods: Patients 40-75 y, with primary idiopathic knee OA and
Kellgren-Lawrence grade of I-III were enrolled in a 16-wk, double-
blind, placebo (PBO)-controlled study. Randomization was 1:1, strati-
ﬁed by 14-day baseline average daily worst pain (ADWP) score of 4.0-
9.0 (0-10 point numeric rating scale), to a single injection of ultra-
sound-guided IA onabotA (200 U) or PBO in the study knee. Primary
efﬁcacy endpoint was 14-day ADWP score change from baseline at wks
4, 8, and 12, jointly analyzed using repeated measures analysis of
covariance for between-group comparisons, adjusted for baseline
ADWP score; missing scores were imputed. 5 pain model evaluations
were conducted at baseline, day 1 pre-injection, and wks 4, 8, and 12:1) quantitative sensory testing of joint pain by pressure-pain threshold
(PPT) at 3 sites over the knee joint (3 cm medial, superior, or lateral to
edge of patella; 3-site average); 2) spreading sensitization testing by
PPT from the tibialis anterior muscle and ipsilateral extensor carpi
radialis longus muscle; 3) wind-up-like pain intensity (0-10 visual
analog scale) to experimental pressure pain stimuli using an automatic
pressure algometer to deliver 1 stimulus or 10 repeated stimuli (1 Hz)
over the tibialis anterior muscle and to the most painful site of the
study knee; 4) cuff algometry, which evaluated PPT via the mean of 3
measurements; 5) mapping of the total area of knee pain. Pain model
endpoints were analyzed using a Wilcoxon rank-sum test (calculated
by analysis of variance of ranked scores) without baseline covariate or
imputation.
Baseline Pain DETECT (PD-Q) scores were used post-hoc to classify
patients into pain subgroups of nociceptive (PD-Q12) or non-noci-
ceptive (13).
Results: Of 170 screened patients, 121 were randomized to onabotA
(n¼61) or PBO (n¼60); mean age 62.3 y, all Caucasian, and similar
numbers of men and women. No clinically relevant between-group
baseline differences were observed. The primary efﬁcacy analysis yiel-
ded no signiﬁcant difference between onabotA and PBO for the change
from baseline in ADWP score to the 3 time points (P¼0.70). Most pain
model tests showed no signiﬁcant difference at any time point. PPT in
the tibialis showed a trend toward improvement with onabotA at wks 4
(P¼0.08) and 8 (P¼0.07; Fig 1A). A similar trend was observed in wind-
up-like pain for the tibialis (wk 12, P¼0.13; Fig 1B). Posthoc analyses in
the 68 nociceptive pain patients showed signiﬁcant between-group
differences favoring onabotA for improved PPT over the tibialis at wks 4
(P¼0.03) and 8 (P¼0.02), with a trend at wk 12 (P¼0.13) and a trend for
the knee at wk 4 (P¼0.11; Fig 2A). A similar trend favoring onabotAwas
seen at wk 8 (P¼0.15) for wind-up-like pain at both tibialis and knee
(Fig 2B). The nociceptive subgroup also reported signiﬁcant pain relief
(P¼0.02; WOMAC pain score) favoring onabotA at wk 8, consistent with
a trend in daily worst pain intensity (P¼0.13).
Conclusion: This exploratory study found no signiﬁcant between-
group differences in the primary efﬁcacy endpoint. Pain model evalu-
ations indicated positive trends favoring onabotA. Post-hoc analyses in
the nociceptive subgroup showed that onabotA signiﬁcantly improved
outcomes in selected mechanistic pain models compared with PBO, in
parallel with reported pain relief. Mechanistic pain model evaluations
showed a larger trend of separation in both peripheral and spreading
pain (ie, central sensitization) than traditional clinical pain scores.
Disclosure: Funded by Allergan.39
RISK OF BIAS AND BRAND EXPLAIN THE OBSERVED INCONSISTENCY
IN TRIALS ON GLUCOSAMINE FOR OSTEOARTHRITIS:A META-
ANALYSIS OF PLACEBO-CONTROLLED TRIALS
P.R. Eriksen. The Parker Inst., Copenhagen, Denmark
Purpose: the aim of this study was to determine whether study
sponsor, chemical formulation, brand of glucosamine, and/or risk of bias
explain observed inconsistencies in trial ﬁndings of glucosamine’s
